Cover Image

Metastatic melanoma and vemurafenib: novel approaches

Ramon Andrade De Mello
  • Ramon Andrade De Mello
    Department of Medical Oncology. Portuguese Oncology Institute; Department of Medicine, Faculty of Medicine, University of Porto, Portugal |


Metastatic melanoma (MM) presents a treatment challenge to oncologists worldwide. Dacarbazine is the first line chemotherapy treatment for MM, though the overall response rates are very poor. Recently, the v-raf murine sarcoma viral oncogene homolog B1 (BRAF) V600 mutation was found to play a main role in MM. This mutation is present in 40-60% of melanoma patients. Vemurafenib is a BRAF kinase inhibitor that showed impressive results in phase I-III trials and was thus recently approved for the treatment of MM. This paper will briefly focus on vemurafenib in the treatment of MM and highlight concerns.


malignant melanoma; vemurafenib; BRAF; metastatic disease; skin cancer

Full Text:

Submitted: 2012-01-09 19:58:00
Published: 2012-05-17 14:25:35
Search for citations in Google Scholar
Related articles: Google Scholar
Abstract views:


Article Metrics

Metrics Loading ...

Metrics powered by PLOS ALM

Copyright (c) 2012 Ramon Andrade De Mello

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
© PAGEPress 2008-2018     -     PAGEPress is a registered trademark property of PAGEPress srl, Italy.     -     VAT: IT02125780185